FDA Permits New Sunscreen Ingredient After 20 Years
The sunscreen ingredient, which has been marketed internationally for years, is considered generally recognized as safe and effective for use in adults and pediatric patients aged 6 months and older.
Edited
Kathryn Wighton
Conexiant June 9, 2026
Objective:
To announce the addition of bemotrizinol to the OTC sunscreen monograph.
Key Findings:
Bemotrizinol provides protection against both UVA and UVB radiation, as stated by the FDA.
It has low systemic absorption following topical use, according to the FDA.
The ingredient has been marketed in Europe and other countries prior to U.S. authorization, as noted by the FDA.
Interpretation:
Limitations:
The FDA's action does not approve any specific sunscreen product containing bemotrizinol.
Conclusion:
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Bio:Kathryn Wighton is an editor with Conexiant, where her byline appears in OB/GYN coverage. Her current editorial work includes reporting on reproductive medicine topics, including uterus transplantation, uterine-factor infertility, assisted reproduction, pregnancy outcomes, and neonatal outcomes.
Her published work in BMJ has focused on COVID-19 vaccination policy and communication for children and adolescents, including vaccination decisions for children under 5 years of age, consent conversations for teenagers, and broader questions around pediatric and adolescent COVID-19 immunization in the United Kingdom.
